跳至主要内容
临床试验/NCT00871611
NCT00871611Unknown不适用

Prevalence of Anderson - Fabry Disease in Patients With Left Ventricular Hypertrophy

Medical University of Vienna1 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
4,000
试验地点
1
主要终点
Prevalence of Anderson - Fabry disease

研究概览

简要总结

The prevalence of Anderson - Fabry disease in patients with left ventricular hypertrophy is unclear. The investigators will examine urine - α - Galactosidase activity and globotriaosylceramide isoforms in these patients.

详细描述

Anderson - Fabry disease (AFD) is a rare, X - linked hereditary systemic lysosomal storage disorder which usually affects the heart. The reported incidence of AFD is between 1 in 117000 and 1 in 240000 live births. Due to a deficiency of the enzyme α - galactosidase, glycosphingo-lipids, primarily globotriaosylceramide, are stored also in endothelial and myocardial cells, leading to morphologic and functional changes. AFD-cardiomyopathy progresses with age and with the course of the disease, leading to reduced life expectancy. The investigators hypothesize, that AFD could be underdiagnosed in patients with only mild or moderate left ventricular myocardial hypertrophy. Early diagnosis of AFD may be relevant since affected patients might benefit from enzyme replacement therapy at early stage of disease. The investigators will examine 4000 consecutive patients with an echocardiographically measured interventricular septum thickness of ≥ 12mm. Urine samples will be collected and Gb3-isoforms, creatinine and α - Galactosidase activity will be measured.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with myocardial septum wall thickness ≥ 12mm

排除标准

  • Patients < 18 years
  • Patients unable to provide urine sample

结局指标

主要结局

Prevalence of Anderson - Fabry disease

时间窗: 2 years

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验